What is HC Wainwright's Estimate for DNLI FY2026 Earnings?

Key Points

• HC Wainwright forecasts Denali will lose $1.61 per share in FY2026 and maintains a “Strong Buy” rating. It also projects losses narrowing to $0.14 per share by FY2030.
• Denali reported quarterly EPS of $0.37, beating the consensus estimate of a $0.27 loss, while revenue of $17.78 million exceeded expectations of $12.67 million.
• Analyst sentiment is broadly positive: MarketBeat reports a “Moderate Buy” consensus rating and a $36.15 average price target, though the article notes one Sell rating.

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities researchers at HC Wainwright issued their FY2026 EPS estimates for Denali Therapeutics in a research note issued to investors on Wednesday, November 4th. HC Wainwright analyst A. Ghosh forecasts that the company will earn ($1.61) per share for the year. HC Wainwright currently has a "Strong-Buy" rating on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.70) per share. HC Wainwright also issued estimates for Denali Therapeutics' Q4 2026 earnings at ($0.62) EPS, FY2027 earnings at ($2.38) EPS, FY2028 earnings at ($1.77) EPS, FY2029 earnings at ($1.51) EPS and FY2030 earnings at ($0.14) EPS.

DNLI has been the topic of several other research reports. B. Riley Financial lifted their target price on shares of Denali Therapeutics from $30.00 to $35.00 and gave the stock a "buy" rating in a report on Tuesday, August 25th. BTIG Research restated a "buy" rating and issued a $39.00 price target on shares of Denali Therapeutics in a research report on Wednesday. Morgan Stanley boosted their price objective on shares of Denali Therapeutics from $40.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday. Wedbush upped their price objective on shares of Denali Therapeutics from $23.00 to $24.00 and gave the company an "outperform" rating in a research report on Wednesday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Denali Therapeutics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $36.15.

Denali Therapeutics Trading Down 5.9%

Shares of NASDAQ:DNLI opened at $19.72 on Friday. The stock has a market capitalization of $3.16 billion, a PE ratio of -11.40 and a beta of 1.08. The firm has a fifty day moving average price of $20.25 and a 200 day moving average price of $21.26. Denali Therapeutics has a 1 year low of $13.75 and a 1 year high of $27.30. The company has a current ratio of 6.21, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.64. The firm had revenue of $17.78 million for the quarter, compared to analysts' expectations of $12.67 million. During the same quarter in the prior year, the business posted ($0.74) earnings per share.

Insider Activity

In related news, insider Alexander O. Schuth sold 2,857 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the transaction, the insider owned 281,763 shares in the company, valued at $7,063,798.41. The trade was a 1.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 9.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Denali Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNLI. BlackRock Inc. bought a new stake in Denali Therapeutics in the second quarter valued at about $360,759,000. ADAR1 Capital Management LLC boosted its holdings in Denali Therapeutics by 3,490.9% during the first quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company's stock worth $35,932,000 after buying an additional 1,819,339 shares during the last quarter. Bank of America Corp DE bought a new position in Denali Therapeutics during the second quarter worth about $31,660,000. Bank of New York Mellon Corp acquired a new position in shares of Denali Therapeutics during the 2nd quarter worth about $20,583,000. Finally, Defilade Capital Management L.P. grew its position in shares of Denali Therapeutics by 107.1% during the 1st quarter. Defilade Capital Management L.P. now owns 1,359,969 shares of the company's stock worth $26,111,000 after buying an additional 703,256 shares during the period. Institutional investors own 92.92% of the company's stock.

Key Stories Impacting Denali Therapeutics

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: Denali’s Q3 earnings beat expectations, while Avlayah sales reportedly rose nearly fivefold and reimbursement coverage expanded. The company also has several pipeline catalysts approaching, giving investors reasons to focus on future growth. Zacks article
• Positive Sentiment: Morgan Stanley raised its price target to $42 and maintained an Overweight rating; Wedbush also lifted its target, to $24, with an Outperform rating. These target increases suggest those analysts see potential upside. Analyst target report
• Neutral Sentiment: HC Wainwright’s estimates project ongoing losses in the coming years, including a $0.62-per-share loss in Q4 2026, but a narrower $0.14 loss in 2030. These are analyst forecasts, not company results, and indicate that a path toward profitability may take time.
• Negative Sentiment: Despite the earnings beat, investors may weigh Denali’s continuing expected losses and valuation against its commercial growth and pipeline prospects. Yahoo Finance article

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company's research programs target conditions including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.